{"id":"9e26511e-f180-5069-bc80-42fa6d7e7c56","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:mouse-th","predicate":"increases_in_recorded_experiment","statement":"Injected SA preserved TH-associated measurements after intranigral LPS.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"e8825456-55b1-5fda-ab5c-8e7dae8fd83b","mechanism_event_label":"Injected SA preserved TH-associated measurements after intranigral LPS.","subject":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"object":{"id":"b8fb1867-c481-5838-8b73-b9e18064c4a1","slug":"mouse-lps-th-preservation","display_name":"Mouse TH-associated measures after intranigral LPS","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"e8825456-55b1-5fda-ab5c-8e7dae8fd83b","stable_key":"31b1baa4-4113-5541-b9e7-fe44a5253a07:mouse-th-event","event_type":"experimental_observation","label":"Injected SA preserved TH-associated measurements after intranigral LPS.","description":"**The neuroinflammation experiment used injected treatment.** After intranigral LPS challenge, mice receiving shikimic acid 100 mg/kg intraperitoneally daily for four weeks showed improved motor-related readouts and preservation of TH-associated measures, with lower microglial markers. This is an inflammatory mouse model; human Parkinson disease efficacy, oral brain exposure and a specific molecular target were not established. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)","status":"provisional","compartment":null,"participants":[{"entity":{"id":"67ad4a8f-1bf6-59e5-90a6-97b7709024d3","slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"},"role":"tested factor","stoichiometry":null,"state_label":"SA after LPS challenge","sequence_order":0,"notes":""},{"entity":{"id":"b8fb1867-c481-5838-8b73-b9e18064c4a1","slug":"mouse-lps-th-preservation","display_name":"Mouse TH-associated measures after intranigral LPS","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"increase","sequence_order":1,"notes":""},{"entity":{"id":"e96aad69-74fb-55c6-8378-7d5c281003eb","slug":"lipopolysaccharide","display_name":"Lipopolysaccharide","entity_type_key":"chemical_species"},"role":"model stimulus","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Primary full text retrieved; relevant methods/results/figures reviewed. Selective extraction, not raw-data reanalysis or exhaustive supplemental extraction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_condition","value_text":"prior model challenge","comparator":"LPS challenge without SA","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"lipopolysaccharide","display_name":"Lipopolysaccharide","entity_type_key":"chemical_species"}},{"dimension":"experimental_condition","value_text":"injected","comparator":"LPS challenge without SA","unit":null,"notes":"Condition belongs to the full experimental contrast; do not separate a joint intervention.","entity":{"slug":"shikimic-acid","display_name":"Shikimic acid","entity_type_key":"small_molecule"}},{"dimension":"experimental_contrast","value_text":"{\"intervention\": \"SA after LPS challenge\", \"comparator\": \"LPS challenge without SA\", \"endpoint\": \"Injected SA preserved TH-associated measurements after intranigral LPS.\", \"effect_direction\": \"increase\", \"combination\": \"joint\", \"conditions\": [{\"entity_slug\": \"shikimic-acid\", \"state\": \"injected\"}, {\"entity_slug\": \"lipopolysaccharide\", \"state\": \"prior model challenge\"}]}","comparator":null,"unit":null,"notes":"Explicit extracted experimental comparison; source-derived draft.","entity":null},{"dimension":"experimental_model","value_text":"Mouse; SA 100 mg/kg intraperitoneal daily for four weeks.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Inflammatory mouse model, not human Parkinson disease treatment or measured oral brain target engagement.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Injected SA preserved TH-associated measurements after intranigral LPS.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model. | 2023 | DOI 10.3389/fphar.2023.1265571 | PMID 38026972 | https://pubmed.ncbi.nlm.nih.gov/38026972/ | https://doi.org/10.3389/fphar.2023.1265571 | https://pmc.ncbi.nlm.nih.gov/articles/PMC10652795/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference lines 65-65; exact primary location described in quoted passage where extracted.","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"11852163-5c35-5a3f-9d48-ab661eae6a9e","evidence_kind":"source_excerpt","locator":"Lines 65-65","start_line":65,"end_line":65,"excerpt":"**The neuroinflammation experiment used injected treatment.** After intranigral LPS challenge, mice receiving shikimic acid 100 mg/kg intraperitoneally daily for four weeks showed improved motor-related readouts and preservation of TH-associated measures, with lower microglial markers. This is an inflammatory mouse model; human Parkinson disease efficacy, oral brain exposure and a specific molecular target were not established. [Shikimic acid (SA) inhibits neuro-inflammation and exerts neuroprotective effects in an LPS-induced <i>in vitro</i> and <i>in vivo</i> model.](https://pubmed.ncbi.nlm.nih.gov/38026972/)","model_system":"Mouse; SA 100 mg/kg intraperitoneal daily for four weeks.","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact excerpt of the retained AI-assisted reviewed reference; primary sources are cited in primary_references and access scope is retained. Not a verbatim quotation from a primary paper.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"e6ae59de-0369-5c2f-8262-57d91302671c","stable_key":"import-31b1baa4-4113-5541-b9e7-fe44a5253a07","title":"Shikimic acid: detailed mechanisms of action (reviewed 5 October 2026)","document_type":"imported_text","citation_label":"Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication.","file_path":"","sha256":"95b1f9e9577661312d67f36e156d2e49326b207f296c1c0e801a5b007fd8e283","revision_id":"cd3237f1-131a-557d-84b5-7543259807b0","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}